Immunotherapy in Advanced Gastroesophageal Tumors: The Best of the Current Knowledge
Gastroesophageal cancers have a poor prognosis despite the use of novel therapies, such as chemotherapy combinations and biologic agents. Recently, immune checkpoint inhibitors (ICIs) have also been introduced into the treatment landscape. The programmed cell death protein 1 (PD-1) inhibitor, pembro...
Saved in:
| Main Author: | Sara De Dosso |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2019-12-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2019.02.008 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immunotherapy and Tumor Heterogeneity in Advanced Goblet Cell Adenocarcinoma of the Appendix: A Case Report
by: Jana Pankovics, et al.
Published: (2024-12-01) -
Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy
by: Yong Liu, et al.
Published: (2024-12-01) -
Current advances in the diagnosis and management of gastroesophageal reflux disease
by: Shu-Wei Liang, et al.
Published: (2022-01-01) -
Debut of Gastroesophageal Reflux Concomitant with Administration of Sublingual Immunotherapy
by: Jacob Juel
Published: (2017-01-01) -
Advances in Colon Cancer Therapy
by: Sara De Dosso
Published: (2022-12-01)